XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition of Pelican Therapeutics (Narrative) (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Mar. 07, 2017
Dec. 31, 2016
Issuance of common stock Pelican, shares     1,331,056      
Accrued liabilities $ 994,964   $ 994,964     $ 1,305,173
Goodwill 2,189,338   2,189,338    
Revenue 470,823 $ 220,233 906,313 $ 220,233    
Net loss (income) $ (2,300,807) $ (1,616,946) $ (8,709,659) $ (9,101,770)    
Pelican Therapeutics, Inc. [Member]            
Percentage of voting interests acquired in acquisition 80.00%   80.00%   80.00%  
Issuance of common stock Pelican, shares     1,331,056      
Percentage of outstanding common shares issued for equity consideration in business acquisition     4.99%      
Accrued liabilities $ 250,000   $ 250,000      
Goodwill $ 2,189,338   2,189,338      
In-process R&D     5,866,000      
Fees and expenses associated with acquisition     $ 559,000      
Percentage of non-controlling interest acquired 20.00%   20.00%      
Revenue     $ 900,000      
Net loss (income)     $ 100,000